UBS Group’s BridgeBio Pharma BBIO Stock Holding History

UBS Group’s Portfolio BBIO Stock Details BBIO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$288M	Hold	3,863,500	–	–	0.04%	489
2026 Q1	$287M	Hold	3,863,500	–	–	0.04%	448
2025 Q4	$296M	Hold	3,863,500	–	–	0.05%	390
2025 Q3	$201M	Hold	3,863,500	–	–	0.03%	581
2025 Q2	$167M	Sell	3,863,500 -22,700	-0.6%	-$826K	0.03%	624
2025 Q1	$134M	Sell	3,886,200 -115,600	-3%	-$3.9M	0.02%	729
2024 Q4	$110M	Sell	4,001,800 -107,500	-3%	-$2.78M	0.02%	863
2024 Q3	$105M	Buy	4,109,300 +245,800	+6%	+$6.45M	0.02%	697
2024 Q2	$97.9M	Hold	3,863,500	–	–	0.02%	664
2024 Q1	$119M	Buy	+3,863,500	New	+$131M	0.03%	568
2023 Q3	–	Sell	-12,100	Closed	-$208K	–	9451
2023 Q2	$208K	Buy	+12,100	New	+$182K	﹤0.01%	5450
2022 Q1	–	Sell	-4,900	Closed	-$82K	–	10243
2021 Q4	$82K	Buy	+4,900	New	+$207K	﹤0.01%	6481

Other funds holding BBIO

Jupiter Topco New York $245B AUM

KKRC

Kohlberg Kravis Roberts & Co New York $5.71B AUM 72.37% 1-Year Est. Return

FCM

Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Viking Global Investors Stamford, Connecticut $35.1B AUM 21.36% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

ACM

Aisling Capital Management New York $472M AUM 106.83% 1-Year Est. Return

UBS Group's BBIO Position: Q2 2026 in Review

UBS Group reduced its BridgeBio Pharma (BBIO) stake by 13% in Q2 2026, selling an estimated $18.9M and leaving 1,757,152 shares worth $131M. The position accounts for 0.02% of the portfolio, ranked #940.

UBS Group first reported a position in BBIO in Q2 2019 and has held it in 29 quarters since. The position peaked at $151M in Q1 2026. 475 funds tracked by Wall St. Rank hold BBIO as of Q2 2026.

UBS Group held 1,757,152 shares of BridgeBio Pharma worth $131M as of Q2 2026.
UBS Group sold 269,669 BridgeBio Pharma shares in Q2 2026, an estimated $18.9M.
BridgeBio Pharma made up 0.02% of UBS Group's portfolio in Q2 2026, its #940 holding.
UBS Group first reported a position in BridgeBio Pharma in Q2 2019 and has held it in 29 quarters since.
UBS Group's BridgeBio Pharma position peaked at $151M in Q1 2026.
475 funds tracked by Wall St. Rank held BridgeBio Pharma as of Q2 2026.

Based on UBS Group's 13F filing for Q2 2026, filed 13 Aug 2026.